[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616945":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":49,"collaborators":26,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":26,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":26,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":39,"whyStopped":26,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Shanghai Eye Disease Prevention and Treatment Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment","EXPERIMENTAL","An LED-RLRL device.",[13],"Device: LED red light",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","SHAM_COMPARATOR","A sham LED-RLRL device.",[19],"Device: Sham LED red light",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","LED red light","An LED-RLRL device (Airdoc PBM-LED, Model No.: AI-PBM01, Beijing Airdoc Technology Co., Ltd.) was adopted. It has a working wavelength of 650 nm, with an output power of 1.39 mW at the light source, and the output power is 1.39 mW ± 0.1 mW at a position 30 mm away from the observation window glass.\n\nTwice daily, 3 minutes per session, 5 days per week, for a total duration of 12 months.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Sham LED red light","A sham LED-RLRL device (identical in appearance but delivering \\\u003C10% of the original device's energy output) .\n\nTwice daily, 3 minutes per session, 5 days per week, for a total duration of 12 months.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Yan Xu, MD","CONTACT","(021)62982727","drxuyan_2004@163.com",[38],{"facility":5,"status":39,"city":40,"state":26,"zip":26,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":26},"RECRUITING","Shanghai","China","CN",{"type":44,"coordinates":45},"Point",[46,47],121.45806,31.22222,{"lat":47,"lon":46},{"type":50,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100616945","led-red-light-in-modulating-choroidal-microcirculation-to-retard-retinal-atrophy-in-pathological-myopia-100616945",false,"NCT07312214","LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia","A Randomized Controlled Trial of LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia","Inclusion Criteria:\n\n* Age range: 18 to 55 years old;\n* Baseline visual acuity: Best Corrected Visual Acuity (BCVA) ≥ 0.1 (LogMAR ≤ 1.0);\n* Meeting the diagnostic criteria for high myopia: Spherical Equivalent (SE) ≤ -6.00 D and Axial Length (AL) ≥ 26.0 mm;\n* Meeting one of the following pathological fundus changes:\n\n  (i) Fundus manifestations corresponding to Category 2 (diffuse chorioretinal atrophy), Category 3 (patchy chorioretinal atrophy), or Category 4 (macular atrophy associated with choroidal neovascularization) of the META-PM classification criteria\\*; (ii) Category 1 of the META-PM classification criteria\\* complicated with macular schisis; (iii) BCVA \\\u003C 0.6;\n\nExclusion Criteria:\n\n* Concurrent with other ophthalmic diseases that may affect visual acuity or outcome assessment, including active myopic choroidal neovascularization (CNV) requiring anti-VEGF therapy, macular hole, vitreous hemorrhage, diabetic retinopathy, retinal detachment, retinal vein occlusion, optic neuritis, uveitis, severe cataract, and glaucoma;\n* Systemic contraindications: Photosensitive epilepsy, autoimmune diseases (e.g., systemic lupus erythematosus), or pregnant\u002Flactating women; Patients who have undergone intraocular surgery, laser treatment, or ophthalmic medication therapy within 3 months prior to enrollment;\n* Patients unable to comply with regular follow-up (e.g., due to remote residence) or with cognitive impairment;\n* Opaque refractive media that hinder fundus examination.","ALL","18 Years","55 Years",{"count":62,"type":63},158,"ESTIMATED","INTERVENTIONAL",[66],"NA","The goal of this clinical trial is to learn if LED repeated low-level red light (RLRL) therapy works to treat pathologic myopia in adults. It will also learn about the safety of LED-RLRL. The main questions it aims to answer are:\n\nDoes LED-RLRL modulate choroidal microcirculation to retard retinal atrophy in pathological myopia? What medical problems do participants have when receiving LED-RLRL therapy? Researchers will compare with a sham device (identical in appearance but delivering \\\u003C10% of the original device's energy output) to see if LED-RLRL works to treat pathologic myopia.\n\nParticipants will:\n\nTake LED-RLRL or sham LED-RLRL twice daily, 3 minutes per session, 5 days per week, for a total duration of 12 months.\n\nVisit the clinic once every 3 months for checkups and tests. Keep a diary of their symptoms and their visual perception.",[69],"Pathologic Myopia",[71,72,73,74],"repeated low-level red light","LED","myopia","treatment","2026-05-12",{"date":77,"type":78},"2026-05-15","ACTUAL",{"date":80,"type":78},"2025-12-31",{"date":82,"type":63},"2028-12-30",{"name":5,"class":6},1]